Answers are grounded in this paper and cite their sources.
This investigation shows TMEM51-AS1 impacts recurrence risks in TNBC patients, pointing to its diagnostic value when combined with DCE-MRI assessments.
Long noncoding RNAs (lncRNAs) participate in various physiological and pathological processes of tumors and have a significant correlation with MRI radiomics. This study investigated the role of lncRNA TMEM51-AS1 in TNBC and probed the role of preoperative DCE-MRI combined with TMEM51-AS1 in risk stratification of postoperative recurrence of TNBC. Real-time quantitative PCR was used to detect the tissue TMEM51-AS1 expression after operation. According to the recurrence and metastasis of patients 1 year after surgery, patients were grouped into high-risk and low-risk groups. The value of preoperative DCE-MRI and TMEM51-AS1 in the assessment of postoperative recurrence and metastasis was analyzed using the receiver operating characteristic curve. CCK-8 and Transwell assays were performed to evaluate the influence of TMEM51-AS1 on TNBC cellular capacities. TMEM51-AS1 was decreased in TNBC tissues, especially in high-risk groups. TMEM51-AS1 expression, Max Slope, and Max Cone were risk factors associated with postoperative recurrent metastasis, and combined three had a high diagnostic value in predicting postoperative recurrent metastasis. Increased TMEM51-AS1 weakened TNBC cell proliferation, migration, and invasion by regulating miR-19a-3p. Combined preoperative DCE-MRI and TMEM51-AS1 testing may be used to predict the risk of postoperative recurrent metastasis in patients with TNBC. TMEM51-AS overexpression may repress TNBC progression by miR-19a-3p, which may guide the subsequent clinical management and improve the survival of TNBC patients.
No takes yet. Share an insight, caveat, or question.
Song et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: